These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

754 related articles for article (PubMed ID: 23696515)

  • 21. Proton density fat-fraction is an accurate biomarker of hepatic steatosis in adolescent girls and young women.
    Rehm JL; Wolfgram PM; Hernando D; Eickhoff JC; Allen DB; Reeder SB
    Eur Radiol; 2015 Oct; 25(10):2921-30. PubMed ID: 25916386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reproducibility of MRI-determined proton density fat fraction across two different MR scanner platforms.
    Kang GH; Cruite I; Shiehmorteza M; Wolfson T; Gamst AC; Hamilton G; Bydder M; Middleton MS; Sirlin CB
    J Magn Reson Imaging; 2011 Oct; 34(4):928-34. PubMed ID: 21769986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accuracy and the effect of possible subject-based confounders of magnitude-based MRI for estimating hepatic proton density fat fraction in adults, using MR spectroscopy as reference.
    Heba ER; Desai A; Zand KA; Hamilton G; Wolfson T; Schlein AN; Gamst A; Loomba R; Sirlin CB; Middleton MS
    J Magn Reson Imaging; 2016 Feb; 43(2):398-406. PubMed ID: 26201284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI-PDFF in NAFLD.
    Kim BK; Bernstein N; Huang DQ; Tamaki N; Imajo K; Yoneda M; Sutter N; Jung J; Nguyen K; Nguyen L; Le T; Madamba E; Richards L; Valasek MA; Behling C; Sirlin CB; Nakajima A; Loomba R
    Aliment Pharmacol Ther; 2023 Jul; 58(2):229-237. PubMed ID: 37269117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MRI proton density fat fraction is robust across the biologically plausible range of triglyceride spectra in adults with nonalcoholic steatohepatitis.
    Hong CW; Mamidipalli A; Hooker JC; Hamilton G; Wolfson T; Chen DH; Fazeli Dehkordy S; Middleton MS; Reeder SB; Loomba R; Sirlin CB
    J Magn Reson Imaging; 2018 Apr; 47(4):995-1002. PubMed ID: 28851124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Feasibility of modified Dixon MRI techniques for hepatic fat quantification in hepatic disorders: validation with MRS and histology.
    Kang BK; Kim M; Song SY; Jun DW; Jang K
    Br J Radiol; 2018 Sep; 91(1089):20170378. PubMed ID: 29022777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging.
    Lin SC; Heba E; Bettencourt R; Lin GY; Valasek MA; Lunde O; Hamilton G; Sirlin CB; Loomba R
    Aliment Pharmacol Ther; 2017 Mar; 45(6):844-854. PubMed ID: 28116801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease.
    Schwimmer JB; Middleton MS; Behling C; Newton KP; Awai HI; Paiz MN; Lam J; Hooker JC; Hamilton G; Fontanesi J; Sirlin CB
    Hepatology; 2015 Jun; 61(6):1887-95. PubMed ID: 25529941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MRI-determined liver proton density fat fraction, with MRS validation: Comparison of regions of interest sampling methods in patients with type 2 diabetes.
    Vu KN; Gilbert G; Chalut M; Chagnon M; Chartrand G; Tang A
    J Magn Reson Imaging; 2016 May; 43(5):1090-9. PubMed ID: 26536609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy.
    Idilman IS; Aniktar H; Idilman R; Kabacam G; Savas B; Elhan A; Celik A; Bahar K; Karcaaltincaba M
    Radiology; 2013 Jun; 267(3):767-75. PubMed ID: 23382293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease.
    Middleton MS; Van Natta ML; Heba ER; Alazraki A; Trout AT; Masand P; Brunt EM; Kleiner DE; Doo E; Tonascia J; Lavine JE; Shen W; Hamilton G; Schwimmer JB; Sirlin CB;
    Hepatology; 2018 Mar; 67(3):858-872. PubMed ID: 29028128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Pilot Comparative Study of Quantitative Ultrasound, Conventional Ultrasound, and MRI for Predicting Histology-Determined Steatosis Grade in Adult Nonalcoholic Fatty Liver Disease.
    Paige JS; Bernstein GS; Heba E; Costa EAC; Fereirra M; Wolfson T; Gamst AC; Valasek MA; Lin GY; Han A; Erdman JW; O'Brien WD; Andre MP; Loomba R; Sirlin CB
    AJR Am J Roentgenol; 2017 May; 208(5):W168-W177. PubMed ID: 28267360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Value of hydrogen proton magnetic resonance spectroscopy in the determination of liver triglyceride in patients with fatty liver disease and its influencing factors].
    Qu HJ; Wang L; Jin PH; Gao Q; Zhou JX; Song Y; Wang J; Jiang YM; Gong L; Chen GY; Ding JP; Shi JP
    Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):858-863. PubMed ID: 29325281
    [No Abstract]   [Full Text] [Related]  

  • 34. Role of Magnetic Resonance Imaging in the Monitoring of Patients with Nonalcoholic Fatty Liver Disease: Comparison with Ultrasonography, Lipid Profile, and Body Mass Index.
    Makhija N; Vikram NK; Kaur G; Sharma R; Srivastava DN; Madhusudhan KS
    J Clin Exp Hepatol; 2020; 10(2):139-149. PubMed ID: 32189929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis.
    Dennis A; Kelly MD; Fernandes C; Mouchti S; Fallowfield JA; Hirschfield G; Pavlides M; Harrison S; Chakravarthy MV; Banerjee R; Sanyal A
    Front Endocrinol (Lausanne); 2020; 11():575843. PubMed ID: 33584535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantifying steatosis in the liver and pancreas with MRI in patient with chronic liver disease.
    Vieira J; Amorim J; Martí-Bonmatí L; Alberich-Bayarri Á; França M
    Radiologia (Engl Ed); 2020; 62(3):222-228. PubMed ID: 31932016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease by Using Quantitative US.
    Han A; Zhang YN; Boehringer AS; Montes V; Andre MP; Erdman JW; Loomba R; Valasek MA; Sirlin CB; O'Brien WD
    Radiology; 2020 Apr; 295(1):106-113. PubMed ID: 32013792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of water-fat MRI and proton MRS in assessment of hepatic fat and the heterogeneous distribution of hepatic fat and iron in subjects with non-alcoholic fatty liver disease.
    Hui SCN; So HK; Chan DFY; Wong SKH; Yeung DKW; Ng EKW; Chu WCW
    Eur J Radiol; 2018 Oct; 107():7-13. PubMed ID: 30292275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial).
    Loomba R; Sirlin CB; Ang B; Bettencourt R; Jain R; Salotti J; Soaft L; Hooker J; Kono Y; Bhatt A; Hernandez L; Nguyen P; Noureddin M; Haufe W; Hooker C; Yin M; Ehman R; Lin GY; Valasek MA; Brenner DA; Richards L;
    Hepatology; 2015 Apr; 61(4):1239-50. PubMed ID: 25482832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accuracy and precision of proton density fat fraction measurement across field strengths and scan intervals: A phantom and human study.
    Kim HJ; Cho HJ; Kim B; You MW; Lee JH; Huh J; Kim JK
    J Magn Reson Imaging; 2019 Jul; 50(1):305-314. PubMed ID: 30430684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.